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TSLP-tickled mast cells
If you suffer a skin allergy, don’t be so quick 
to blame your T cells; they might not be 
behind it. Allakhverdi and colleagues now 
show on page 253 that mast cells, activated by 
a cytokine from epithelial cells, can jump-
start T cell–independent inflammation.
Skin and epithelial cells irritated by aller-
gens or by injury produce a cytokine called 
thymic stromal lymphopoietin (TSLP). This 
cytokine masterminds a sequence of dendritic 
cell (DC)–mediated reactions that attract 
T helper (Th)-2 cells to the hot zone.
In addition to Th2 cells, however, other cells 
such as mast cells also arrive on the scene. Mast 
cell recruitment and activation was thought to be 
dependent on signals from Th2 cells. But, as 
Allakhverdi et al. now show, mast cells them-
selves bear TSLP receptors and get directly acti-
vated when activated epithelial cells secrete TSLP. 
Thus, the DC-Th2 mediated “axis of allergy” is 
bypassed in favor of an innate immune response.
The direct activation of mast cells by TSLP 
explains the previous finding that mice lacking T 
cells can develop allergy and inflammation when 
given TSLP. It might also explain why 20–30% 
of asthma patients have allergic reactions despite 
having minimal signs of Th2 induction.
An early involvement of innate immunity 
in allergy has previously been suspected, 
  according to senior author Guy Delespesse. 
There are a whole host of clinical observations 
that show that allergy is a follow-up act to 
something other than an antigen-specific trig-
ger, he says. A common cold can heighten 
asthma symptoms, for example, and scratching 
can worsen eczema. TSLP might thus provide 
the direct and immediate connection between 
epithelial trauma and an allergic response. 
A new target for pain relief
Anti-inflammatory lipid mediators help put out flames at an injury site. On 
page 245, Svensson and colleagues now report that these lipids switch off 
pain signals in the spinal cord as well.
Pain occurs when neurons in the periphery get stimulated by tissue 
damage or inflammatory signals such as prostaglandins (PGs). PGs, 
produced by neutrophils at the injury site, bind to their receptors on 
peripheral nerve terminals and trigger a pain message to the central nervous 
system (CNS). Nonneuronal cells of the CNS such as astrocytes and 
microglia get turned on by the incoming message and produce yet more 
PGs and inflammatory cytokines that further amplify the pain signal.
Back at the injury site, pain begins to ease when lipoxin production 
starts. Lipoxins stop inflammation in several ways. These include enhancing 
the production of anti-inflammatory cytokines, preventing the recruitment 
of more neutrophils, and activating macrophages to clean up the mess.
Svensson et al. now report that lipoxins can also act in the CNS. 
They find that astrocytes express receptors for lipoxin. When lipoxin was 
injected systemically or directly into the spine, pain was relieved. Receptor 
activation, Svensson suggests, might suppress the formation of pro-
inflammatory factors in the astrocytes.
Many common pain relievers block PG production by chemically 
inhibiting the PG-producing enzyme. Although Svensson appreciates 
the usefulness of aspirin in combating all manner of aches and pains, she 
speculates that the wide range of targets downstream of lipoxin might 
make lipoxin-induced pain management a better strategy. 
Imaging a dying tumor
When T cells come across a tumor, they kill off 
the outer layers and then move in, say Boissonnas 
et al. on page 345. The authors use intravital 
microscopy to show that this infiltration and 
obliteration of the tumor is antigen dependent.
Intravital microscopy has previously revealed 
the killing strategy of T cells in lymphoid tissue. The 
T cells use a search-and-destroy tactic, moving rapidly 
through the tissue while constantly scanning for 
targets. When an enemy is identified, they stop, kill 
the intruder, and then resume the hunt. The T cells’ method of killing inside a 
solid nonlymphoid tumor environment, however, is less certain. “We knew that 
the immune system can reject tumors,” says senior author Sebastian Amigorena, 
“but we didn’t really understand how T cells function inside the tumor.”
Amigorena and his colleagues now show that the initial contact between 
anti-tumor T cells and their targets is at the tumor periphery. Once the 
peripheral cells are dead, the T cells attack the next layer and the next, thus 
gradually diminishing the tumor mass. This method of tumor destruction by 
T cells is dependent on antigen expression by the tumor cells. In tumors that 
do not express a cognate antigen, T cells are initially detected in the 
periphery but then drift away when they fail to find an appropriate target.
The team now plans to use their imaging set-up to investigate 
whether anti-tumor T cells are doing the killing on their own or, as seen 
in lymphoid tissue, are recruiting other immune cells. Knowing what cells 
work against a tumor might lead to anti-tumor strategies that help these 
cells penetrate to a tumor’s depths. 
Solid tumors are 
destroyed (top) only 
when tumor cells (green) 
express antigen.
Stimulated epithelial cells release TSLP, which 
activates mast cells to produce IL-13.